Pharmacological Management of Heart Failure

Digoxin inhibits the sodium-potassium ATPase pump on the cardiac muscle cell membrane. With this pump inhibited, the sodium gradient that normally drives the sodium-calcium exchanger weakens, and the exchanger moves less calcium out of the cell. The resulting rise in intracellular calcium increases the amount of calcium available for each contraction, producing a modest increase in contractile force.

Unlike catecholamine-based inotropes, digoxin produces this effect without significantly increasing myocardial oxygen demand. Digoxin also increases vagal tone, slowing conduction through the atrioventricular node, an effect that is now considered at least as clinically important as its modest inotropic action.

In modern heart failure care, digoxin does not improve survival. Its role is limited to reducing hospitalizations for heart failure in patients who remain symptomatic despite optimized therapy with the four pillars, and it requires a low target blood level rather than the traditional, higher therapeutic range once used historically.

Digoxin has a narrow therapeutic index, meaning the gap between an effective dose and a toxic dose is small. Hypokalemia is the single most important risk factor for toxicity, since potassium and digoxin compete for the same binding site on the sodium-potassium ATPase pump, so low potassium effectively increases the drug action at any given blood level.

A classic and distinctive feature of digoxin toxicity is visual disturbance, including a yellow-green tinge to vision and halos around lights, caused by the drug effect on retinal photoreceptors. Digoxin toxicity can also cause dangerous cardiac arrhythmias, and any patient with risk factors for toxicity who develops new gastrointestinal symptoms, visual changes, or arrhythmia should be evaluated for it.

Cardiogenic shock is the most severe presentation of heart failure: the heart can no longer maintain adequate blood pressure and organ perfusion, even with maximal support. While inotropes increase the force of cardiac contraction, vasopressors work through a different mechanism entirely, constricting blood vessels to raise blood pressure. This is an important distinction: a patient in cardiogenic shock may need one, the other, or both, depending on whether the primary problem is inadequate pumping force, inadequate vascular tone, or both together.

Norepinephrine, which acts primarily on alpha-1 adrenergic receptors to produce vasoconstriction, is the preferred vasopressor in cardiogenic shock. It is often combined with an inotrope such as dobutamine or milrinone from Section 3 when both vasoconstriction and improved contractility are needed.